Dr. Lal Path Labs Ltd. — PPTs, 31-07-2025: Investor Presentation

1. **Financial Highlights:**

Q1 FY26 saw revenue growth of 11.3% YoY to Rs. 670 Cr, driven by 10.7% sample volume increase. EBITDA jumped 13.1% to Rs. 192 Cr (28.7% margin), and PAT surged 24.3% to Rs. 134 Cr (20.0% margin). Strong cash flow supports self-funded growth. #LalPathLabs #Q1FY26

2. **Strategic Initiatives & Growth Drivers:**

Focus on calibrated network expansion into core metros and deeper penetration in Tier 3/4 cities. Growth drivers include a deepening advanced test portfolio (Genomics, Auto-immunity, high-complexity) and the growing "SwasthFit" program (27% Q1 contribution). Tech investments like AI-integrated lab systems enhance efficiency. #GrowthStrategy #Diagnostics

3. **Business Developments:**

Integration of Suburban Diagnostics is now contributing to West India performance. Company launched "Screening Early-stage Liver Cancer" (first in India) and "Amyloid Typing" (first in South Asia). Network includes 298 labs and over 6,600 Patient Service Centers as of March 2025. #Expansion #ProductLaunch

4. **Market Position & Competitive Advantage:**

As India's leading diagnostics company with 75+ years of experience, Dr. Lal PathLabs leverages its established brand and pan-India integrated network. Its efficient hub-and-spoke model and strong digital infrastructure provide scale advantages and cost efficiencies, fortifying its market leadership. #MarketLeader #CompetitiveEdge

5. **Investor Implications:**

The strong Q1 performance, driven by volume growth and strategic network expansion, indicates positive growth potential. A robust balance sheet and focus on operational excellence via digital transformation underpin a clear roadmap for sustainable long-term value creation. #InvestorOutlook #PathLabs